# KEYLYNK-012 (NCT04380636)

> Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab plus olaparib; pembrolizumab
- Indication: unresectable stage III non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04380636
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
- Interventions: Pembrolizumab; Olaparib; Placebo for olaparib; Etoposide; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed; Thoracic Radiotherapy; Durvalumab
- Enrollment: 870
- Primary outcome: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on KEYLYNK-012 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keylynk-012-nct04380636

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04380636", "email": "<work email>"}; the inbox owner confirms by the emailed link.